Covered recipient · General Payments record
DAVID S GREENSTEIN
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$113,294.19
337 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $61,256.50 | 24 |
| Honoraria | $25,600.00 | 8 |
| Compensation for serving as faculty or as a speaker for a medical education program | $9,747.00 | 3 |
| Food and Beverage | $7,291.50 | 273 |
| Consulting Fee | $5,780.00 | 3 |
| Travel and Lodging | $3,490.24 | 23 |
| Education | $128.95 | 3 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Organon LLC | $27,048.11 | 30 |
| Botanix SB Inc | $21,078.36 | 22 |
| ABBVIE INC. | $16,593.48 | 58 |
| Lilly USA, LLC | $16,188.26 | 28 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $12,212.21 | 31 |
| Galderma Laboratories, L.P. | $12,151.15 | 36 |
| E.R. Squibb & Sons, L.L.C. | $4,507.49 | 11 |
| UCB, Inc. | $787.17 | 19 |
| Janssen Biotech, Inc. | $633.23 | 16 |
| GENZYME CORPORATION | $473.59 | 15 |
| Novartis Pharmaceuticals Corporation | $459.14 | 18 |
| PFIZER INC. | $300.84 | 9 |
| Incyte Corporation | $257.46 | 14 |
| Regeneron Healthcare Solutions, Inc. | $200.71 | 6 |
| Arcutis Biotherapeutics, Inc. | $141.76 | 10 |
| LEO Pharma Inc. | $54.94 | 3 |
| STRATA Skin Sciences, Inc. | $54.40 | 6 |
| Elekta, Inc. | $49.04 | 1 |
| Verrica Pharmaceuticals Inc. | $39.76 | 2 |
| Alexion Pharmaceuticals, Inc. | $34.04 | 1 |
| Amgen Inc. | $29.05 | 1 |
Page 5 of 7; records 201–250 of 337 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DAVID S GREENSTEIN
NPI 1205931789 · CMS profile ID 191041
Allopathic & Osteopathic Physicians / Dermatology
BEVERLY, MA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 5 of 7; records 201–250 of 337 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1205931789?year=2025&recipient=provider&page=5#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DAVID S GREENSTEIN, NPI 1205931789, CMS profile ID 191041. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 7; records 201–250 of 337 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1205931789?year=2025&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). DAVID S GREENSTEIN, NPI 1205931789, CMS profile ID 191041. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 7; records 201–250 of 337 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1205931789?year=2025&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- DAVID S GREENSTEIN, NPI 1205931789, CMS profile ID 191041, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 7; records 201–250 of 337 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1205931789?year=2025&recipient=provider&page=5#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
337 matching records · $113,294.19 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 201–250 of 337.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | $27.52 | 05/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174629746 | CMS |
| ABBVIE INC. | $20.63 | 05/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201962760 | CMS |
| Galderma Laboratories, L.P. | $3,600.00 | 05/16/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234647940 | CMS |
| ABBVIE INC. | $6.61 | 05/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201962758 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $70.00 | 05/15/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250989361 | CMS |
| Organon LLC | $7,200.00 | 05/14/2025 | Honoraria | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237672434 | CMS |
| STRATA Skin Sciences, Inc. | $13.87 | 05/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1253014588 | CMS |
| Lilly USA, LLC | $31.13 | 05/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186617850 | CMS |
| Galderma Laboratories, L.P. | $121.93 | 05/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234647938 | CMS |
| Lilly USA, LLC | $23.42 | 05/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186572402 | CMS |
| Galderma Laboratories, L.P. | $9.00 | 05/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234647936 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $45.18 | 05/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250989329 | CMS |
| Galderma Laboratories, L.P. | $5.20 | 05/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234647934 | CMS |
| UCB, Inc. | $148.11 | 05/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224428656 | CMS |
| Lilly USA, LLC | $1,250.00 | 04/30/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186594686 | CMS |
| Novartis Pharmaceuticals Corporation | $21.56 | 04/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200315741 | CMS |
| Organon LLC | $56.00 | 04/30/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237672410 | CMS |
| Organon LLC | $82.00 | 04/30/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237672412 | CMS |
| ABBVIE INC. | $7.26 | 04/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201962756 | CMS |
| Lilly USA, LLC | $1,250.00 | 04/29/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186572400 | CMS |
| Janssen Biotech, Inc. | $31.82 | 04/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174630038 | CMS |
| PFIZER INC. | $34.42 | 04/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228952816 | CMS |
| GENZYME CORPORATION | $34.26 | 04/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233275807 | CMS |
| Galderma Laboratories, L.P. | $10.73 | 04/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234647932 | CMS |
| ABBVIE INC. | $27.42 | 04/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201962754 | CMS |
| ABBVIE INC. | $19.95 | 04/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201962752 | CMS |
| Botanix SB Inc | $6,300.00 | 04/17/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246259801 | CMS |
| Botanix SB Inc | $119.00 | 04/17/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246259803 | CMS |
| Botanix SB Inc | $97.58 | 04/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246259805 | CMS |
| STRATA Skin Sciences, Inc. | $5.60 | 04/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1253014586 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $20.01 | 04/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250989385 | CMS |
| ABBVIE INC. | $22.71 | 04/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201962750 | CMS |
| UCB, Inc. | $32.25 | 04/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224428654 | CMS |
| Lilly USA, LLC | $26.02 | 04/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186593906 | CMS |
| UCB, Inc. | $29.95 | 04/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224428652 | CMS |
| Organon LLC | $24.70 | 04/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237672396 | CMS |
| Galderma Laboratories, L.P. | $8.10 | 04/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234647930 | CMS |
| Incyte Corporation | $26.86 | 04/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226012697 | CMS |
| Janssen Biotech, Inc. | $4.70 | 03/31/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174629213 | CMS |
| Janssen Biotech, Inc. | $38.76 | 03/31/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174629585 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $1,444.00 | 03/31/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250989335 | CMS |
| Incyte Corporation | $5.94 | 03/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226012677 | CMS |
| E.R. Squibb & Sons, L.L.C. | $20.33 | 03/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184903950 | CMS |
| Organon LLC | $6.47 | 03/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237672386 | CMS |
| PFIZER INC. | $36.77 | 03/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231502096 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $3,249.00 | 03/26/2025 | Compensation for serving as faculty or as a speaker for a medical education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250989359 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $119.10 | 03/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250989371 | CMS |
| Galderma Laboratories, L.P. | $15.76 | 03/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234647928 | CMS |
| ABBVIE INC. | $11.29 | 03/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201962748 | CMS |
| Organon LLC | $52.60 | 03/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237672406 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $35,170.66 | 30 |
| PY2024 | Principal investigator | $285,290.72 | 172 |
| PY2023 | Recipient | $4,835.00 | 4 |
| PY2023 | Principal investigator | $440,477.94 | 146 |
| PY2022 | Recipient | $4,351.00 | 4 |
| PY2022 | Principal investigator | $773,140.12 | 102 |
| PY2021 | Recipient | $6,450.00 | 3 |
| PY2021 | Principal investigator | $593,960.20 | 155 |
| PY2020 | Recipient | $9,712.36 | 7 |
| PY2020 | Principal investigator | $597,327.20 | 74 |
| PY2019 | Recipient | $24,182.00 | 3 |
| PY2019 | Principal investigator | $769,667.26 | 30 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
30 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,204.28 | 11/20/2025 | Non-covered Recipient Entity CUTANEOUS CLINICAL TRIALS LLC | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184263433 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,125.00 | 11/12/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223288217 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,125.00 | 11/12/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223288219 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $200.00 | 11/05/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223287995 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $20.00 | 11/05/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223287997 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $40.00 | 11/05/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223287999 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,300.00 | 11/05/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223288001 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,500.00 | 11/05/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223288003 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,200.00 | 11/05/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223288005 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $119.78 | 10/08/2025 | Non-covered Recipient Entity NORTHEAST DERMATOLOGY | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190313757 |
| Principal investigator 1 | Eli Lilly and Company | $14,164.00 | 06/25/2025 | Non-covered Recipient Entity CUTANEOUS CLINICAL TRIALS, LLC | OBSERVATION PRIORITY E SHORT - LEBRIKIZUMAB - ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187880996 |
| Principal investigator 1 | Eli Lilly and Company | $5,360.00 | 04/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB | No dispute reported | 06/30/2026 | 1187872309 |
| Principal investigator 1 | Eli Lilly and Company | $2,402.46 | 03/10/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES AND RESEARCH INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1187874199 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $385.00 | 01/22/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223274377 |
| Principal investigator 1 | Incyte Corporation | $196.10 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498602 |
| Principal investigator 1 | Incyte Corporation | $21.20 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498606 |
| Principal investigator 1 | Incyte Corporation | $37.66 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498610 |
| Principal investigator 1 | Incyte Corporation | $42.40 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498612 |
| Principal investigator 1 | Incyte Corporation | $196.10 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498616 |
| Principal investigator 1 | Incyte Corporation | $21.52 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498620 |
| Principal investigator 1 | Incyte Corporation | $16.14 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498624 |
| Principal investigator 1 | Incyte Corporation | $16.14 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498628 |
| Principal investigator 1 | Incyte Corporation | $79.50 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498632 |
| Principal investigator 1 | Incyte Corporation | $111.30 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498636 |
| Principal investigator 1 | Incyte Corporation | $10.76 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498640 |
| Principal investigator 1 | Incyte Corporation | $10.76 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498644 |
| Principal investigator 1 | Incyte Corporation | $16.14 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498648 |
| Principal investigator 1 | Incyte Corporation | $185.50 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498652 |
| Principal investigator 1 | Incyte Corporation | $42.40 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498656 |
| Principal investigator 1 | Incyte Corporation | $21.52 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498660 |